Stock ZVRA ZEVRA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Zevra Therapeutics, Inc.

Equities

ZVRA

US4884452065

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
4.66 USD +3.79% Intraday chart for Zevra Therapeutics, Inc. -1.48% -28.85%
May. 13 Transcript : Zevra Therapeutics, Inc. - Shareholder/Analyst Call
May. 08 Earnings Flash (ZVRA) ZEVRA THERAPEUTICS Reports Q1 Revenue $3.4M MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Zevra Therapeutics to Participate at Upcoming Investor Events
AQ
Zevra Therapeutics: Q1 Earnings Snapshot
AQ
Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
PR
Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024
AQ
Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024
AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
PR
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
PR
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility
AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
PR
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
AQ
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
AQ
Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
AQ
Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024
AQ
Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
AQ
Zevra Therapeutics to Participate at Upcoming Investor Conferences
AQ
Zevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
AQ
Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, to the Board of Directors
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ZVRA Stock
  4. News Zevra Therapeutics, Inc.
  5. Press Releases